Level of Serum Neurone Specific Enolase and Prognosis in Small Cell Lung Cancer: A Systematic Review_Chinese Journal of Evidence-Based Medicine

Authors：

TANG Jianhua ¹ , ZHANG zhihua ¹ ,  WANG Rui ² , TANG Huilin ³ , ZHANG Guiyun ² , LONG Liyan ² , CHEN liangan ²

1. The First Affiliated Hospital of Hebei Northern College, Zhangjiakou 075000, China;2. Evidence-Based Medicine Centre of Chinese PLA General Hospital, Beijing 100853, China;3. Peking University Third Hospital, Beijing 100191, China;

Corresponding author：

WANG Rui, Email: wangrui301@vip.sina.com

Keywords：

Neurone specific enolase; Small cell lung cancer; Prognosis; Systematic Review

DOI：

10.7507/1672-2531.20090016

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To evaluate the prognostic value of the level of serum neurone specific enolase (NSE) in patients with small cell lung cancer (SCLC).
Methods 　We searched MEDLINE, EMbase, CBMdisc, and The Cochrane Central Register of Controlled Trials (1950 to December 2007). Studies meeting the eligibility criteria were retrieved and their bibliographies were checked for other relevant publications. The quality of included studies was evaluated by 2 reviewers independently. Meta-analyses were performed for the results of homogeneous studies using STATA 7.0 software.
Results 　Nine studies involving 2 021 SCLC patients were included. About 66.0% of patients had high serum levels of NSE, according to the cut-off value defined by the authors. The hazard ratio (HR) of high levels of NSE for overall survival (OS) was 1.27 times of that of low levels of NSE for OS in SCLC patients (95% CI 1.19 to 1.35, P=0.281).
Conclusion 　 Patients with high levels of NSE appear to have a poorer OS compared with those with low levels of NSE, thus the level of NSE has a prognostic value in SCLC patients. Due to the potential publication bias, selection bias, and measurement bias among these studies, the conclusion should be interpreted carefully. More high-quality homogeneous studies are required to accurately evaluate the prognostic value of NSE.

Citation： TANG Jianhua,ZHANG zhihua,WANG Rui,TANG Huilin,ZHANG Guiyun,LONG Liyan,CHEN liangan. Level of Serum Neurone Specific Enolase and Prognosis in Small Cell Lung Cancer: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2009, 09(1): 76-80. doi: 10.7507/1672-2531.20090016 Copy

1.	Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2.	Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5.	Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6.	Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7.	Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8.	Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9.	历为良, 钱桂生, 黄桂君, 等. 人肺癌组织细胞Na/H交换蛋白-1基因的表达与其抗凋亡的关系. 中国癌症杂志, 2000, 10(2): 14.
10.	马兰海. 血清神经元特异性烯醇化酶对小细胞肺癌的诊断价值探讨. 放射免疫学杂志, 2002, 15(6): 351-352.
11.	刘关键, 吴泰相, 康德英. Meta-分析中的统计学过程. 中国临床康复, 2003, 7(4): 538-539.
12.	Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13.	JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14.	Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15.	Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16.	金炳文, 赵兰, 周彩存, 等. 神经元特异性烯醇化酶检测在小细胞肺癌预后中的价值. 中华结核和呼吸杂志, 2001, 24(12): 722-724.
17.	Bremnes RM, Sundstrom S, Aasebø U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18.	Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19.	宋丽华, 宋现让, 张锡芹, 等. 小细胞肺癌患者预后因素分析. 中华肿瘤杂志, 2004, 26(7): 413-416.
20.	刘丽诗, 胡华成. 神经元特异性烯醇化酶、癌胚抗原、乳酸脱氢酶在小细胞肺癌中的预后价值比较. 苏州大学学报(医学版), 2005, 25 (2): 261-264.

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5. Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7. Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8. Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9. 历为良, 钱桂生, 黄桂君, 等. 人肺癌组织细胞Na/H交换蛋白-1基因的表达与其抗凋亡的关系. 中国癌症杂志, 2000, 10(2): 14.
10. 马兰海. 血清神经元特异性烯醇化酶对小细胞肺癌的诊断价值探讨. 放射免疫学杂志, 2002, 15(6): 351-352.
11. 刘关键, 吴泰相, 康德英. Meta-分析中的统计学过程. 中国临床康复, 2003, 7(4): 538-539.
12. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13. JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14. Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16. 金炳文, 赵兰, 周彩存, 等. 神经元特异性烯醇化酶检测在小细胞肺癌预后中的价值. 中华结核和呼吸杂志, 2001, 24(12): 722-724.
17. Bremnes RM, Sundstrom S, Aasebø U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18. Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19. 宋丽华, 宋现让, 张锡芹, 等. 小细胞肺癌患者预后因素分析. 中华肿瘤杂志, 2004, 26(7): 413-416.
20. 刘丽诗, 胡华成. 神经元特异性烯醇化酶、癌胚抗原、乳酸脱氢酶在小细胞肺癌中的预后价值比较. 苏州大学学报(医学版), 2005, 25 (2): 261-264.

Previous Article
临床病理讨论——咳嗽、咳白痰、双肺阴影
Next Article
12例重症军团菌肺炎回顾性分析

Chinese Journal of Evidence-Based Medicine

Level of Serum Neurone Specific Enolase and Prognosis in Small Cell Lung Cancer: A Systematic Review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content